Join Growin Stock Community!

Amgen inc.AMGN.US Overview

US StockHealthcare
(No presentation for AMGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AMGN AI Insights

AMGN Overall Performance

AMGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AMGN Recent Performance

-3.26%

Amgen inc.

-3.61%

Avg of Sector

-2.16%

S&P500

AMGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AMGN Key Information

AMGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AMGN Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Price of AMGN

AMGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AMGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
14.30
PE Ratio (TTM)
27.24
Forward PE
17.01
PS Ratio (TTM)
5.69
PB Ratio
23.62
Price-to-FCF
25.09
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.25%
Net Margin
20.98%
Revenue Growth (YoY)
9.95%
Profit Growth (YoY)
20.17%
3-Year Revenue Growth
12.99%
3-Year Profit Growth
10.61%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
14.30
PE Ratio (TTM)
27.24
Forward PE
17.01
PS Ratio (TTM)
5.69
PB Ratio
23.62
Price-to-FCF
25.09
Gross Margin
67.25%
Net Margin
20.98%
Revenue Growth (YoY)
9.95%
Profit Growth (YoY)
20.17%
3-Year Revenue Growth
12.99%
3-Year Profit Growth
10.61%

  • When is AMGN's latest earnings report released?

    The most recent financial report for Amgen inc. (AMGN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AMGN's short-term business performance and financial health. For the latest updates on AMGN's earnings releases, visit this page regularly.

  • Where does AMGN fall in the P/E River chart?

    According to historical valuation range analysis, Amgen inc. (AMGN)'s current price-to-earnings (P/E) ratio is 25.81, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of AMGN?

    According to the latest financial report, Amgen inc. (AMGN) reported an Operating Profit of 2.72B with an Operating Margin of 27.57% this period, representing a growth of 17.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AMGN's revenue growth?

    In the latest financial report, Amgen inc. (AMGN) announced revenue of 9.87B, with a Year-Over-Year growth rate of 8.58%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AMGN have?

    As of the end of the reporting period, Amgen inc. (AMGN) had total debt of 54.6B, with a debt ratio of 0.6. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AMGN have?

    At the end of the period, Amgen inc. (AMGN) held Total Cash and Cash Equivalents of 9.13B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AMGN go with three margins increasing?

    In the latest report, Amgen inc. (AMGN) achieved the “three margins increasing” benchmark, with a gross margin of 69.8%%, operating margin of 27.57%%, and net margin of 13.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AMGN's profit trajectory and future growth potential.

  • Is AMGN's EPS continuing to grow?

    According to the past four quarterly reports, Amgen inc. (AMGN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.47. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AMGN?

    Amgen inc. (AMGN)'s Free Cash Flow (FCF) for the period is 961M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 78.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AMGN?

    The latest valuation data shows Amgen inc. (AMGN) has a Price-To-Earnings (PE) ratio of 25.81 and a Price/Earnings-To-Growth (PEG) ratio of -0.56. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.